Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
PRESSMEDDELANDE Active Biotechs årsstämma hölls den 23 maj 2019. I enlighet med styrelsens förslag beslöts att ingen utdelning skulle lämnas. Styrelsens ledamöter och verkställande direktören...
-
PRESS RELEASE The Annual General Meeting of Active Biotech was held on May 23, 2019. In accordance with the Board of Directors' proposal, it was resolved that no dividend would be paid. The...
-
PRESSMEDDELANDE Lund den 3 maj, 2019 - Active Biotech (NASDAQ STOCKHOLM: ACTI) meddelar att data från fas 2-studien LEGATO-HD med laquinimod i Huntingtons sjukdom har blivit utvalt att presenteras...
-
PRESS RELEASE Lund Sweden, May 3, 2019 - Active Biotech (NASDAQ STOCKHOLM: ACTI) announces that data from the Phase 2 LEGATO-HD study of laquinimod in Huntington's disease has been selected to be...
-
Active Biotech (NASDAQ, STOCKHOLM:ACTI) announce that the Election Committee of Active Biotech AB (publ) proposes that Michael Shalmi and Uli Hacksell are appointed new members of the Board of...
-
PRESSMEDDELANDE Lund den 2 maj, 2019 - Active Biotech (NASDAQ, STOCKHOLM:ACTI) meddelar Valberedningens förslag till Årsstämman. Valberedningen för Active Biotech AB (publ) förslår att Michael...
-
PRESS RELEASE Lund 2 May, 2019 - Active Biotech (NASDAQ, STOCKHOLM:ACTI) announce that the Election Committee of Active Biotech AB (publ) proposes that Michael Shalmi and Uli Hacksell are...
-
PRESSMEDDELANDE Active Biotechs årsredovisning för 2018 finns nu tillgänglig på www.activebiotech.com. Årsredovisningen kommer enbart att distribueras digitalt. Ladda ner som PDF Lund den 26...
-
PRESS RELEASE Active Biotech's Annual Report 2018 is now available for download at www.activebiotech.com. The Annual Report will only be digitally distributed. The English version will be...
-
First quarter in brief Active Biotech's partner NeoTX entered clinical collaboration with AstraZeneca to evaluate ANYARA ("naptumumab") in combination with IMFINZI® (durvalumab) in the...